Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.

We sought to determine racial and ethnic differences in perceptions (quality of communication, expectations, and concerns) of germline or somatic DNA sequencing (genomic profiling). Patients with prostate, urothelial, or kidney cancer were surveyed using a questionnaire that assessed previous experience, beliefs, expectations, and concerns regarding genomic profiling. Descriptive statistics and chi-square tests were used to identify factors associated with patients' perceptions of genomic profiling. A total of 150 consecutive patients were enrolled. The majority were male (74%) with a mean age of 68 years old. Most patients underwent somatic testing (54%), 24% undertook germline testing, and 21% undertook both tests. Significant differences were found across racial and/or ethnicity concerning factors that could have influenced patients' decision to pursue genomic profiling, including ability to guide the type of treatment (White: 54.1% vs. other ethnic groups: 43.9%, p = 0.04) and potential to improve treatment response (White: 10.1% vs. other ethnic groups: 22.0%, p = 0.04). Other ethnic group of patients were more concerned about learning that the cancer was less treatable or aggressive (43.8% vs. 27.7%, p = 0.01) and anxious about what would be learnt from genomic profiling (34.4% vs. 21.3, p = 0.01) as compared to White patients. Our findings reinforce the importance of developing culturally tailored education to help patients participate actively in decisions about genomic profiling.

[1]  W. Linehan,et al.  Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. , 2021, The New England journal of medicine.

[2]  Jason Zhu,et al.  Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer , 2020, The Prostate.

[3]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[4]  M. Galsky,et al.  Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results , 2020, Cancer.

[5]  B. Ramaswamy,et al.  Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions. , 2019, JCO precision oncology.

[6]  B. Ramaswamy,et al.  Metastatic breast cancer patient perceptions of somatic tumor genomic testing , 2019, BMC Cancer.

[7]  H. Williams,et al.  Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes. , 2019, Urologic oncology.

[8]  W. Chung,et al.  Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies , 2019, Genetics in Medicine.

[9]  N. Rothman,et al.  Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. , 2019, European urology.

[10]  Jonathan M Marron,et al.  Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience , 2016, Pediatric blood & cancer.

[11]  Kelvin K. W. Chan,et al.  Genomic testing in cancer: Patient knowledge, attitudes, and expectations , 2014, Cancer.

[12]  D. Flum,et al.  Shared decision-making for cancer care among racial and ethnic minorities: a systematic review. , 2013, American journal of public health.

[13]  Barbara A Koenig,et al.  Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. , 2011, Mayo Clinic proceedings.